Evidence map›Paper›PMID 29776990›Full record

Trial reportCirculation. Cardiovascular imaging2018

Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.

Nehal N Mehta, Daniel B Shin, Aditya A Joshi, Amit K Dey, April W Armstrong, Kristina Callis Duffin, Zelma Chiesa Fuxench, Charlotte L Harrington, Rebecca A Hubbard, Robert E Kalb and 15 more

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Cardiovascular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 95 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 7 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01553058 phase4completednot on this map

A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease

TypeinterventionalSponsorUniversity of PennsylvaniaRan2012 to 2016Enrolled97ConditionsPsoriasis, Cardiovascular DiseaseArmsAdalimumab (Humira), Placebo Injection, NB-UVB phototherapy
NCT01866592 phase4completednot on this map

Vascular Inflammation in Psoriasis - Extension Study

TypeinterventionalSponsorUniversity of PennsylvaniaRan2013 to 2016Enrolled81ConditionsPsoriasis, Cardiovascular DiseaseArmsAdalimumab
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 7 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.The Cochrane database of systematic reviews · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Cardiovascular Disease and Psoriasis.Dermatology and therapy · 2026
    Review
  19. Article
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 2 institutions in 1 country.

Nehal N MehtaCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (N.N.M., A.A.J., A.K.D., C.L.H., M.P.P.). nehal.mehta@nih.gov Joel.Gelfand@uphs.upenn.edu.
Daniel B ShinDepartment of Dermatology, Perelman School of Medicine (D.B.S., Z.C.F., J.T., S.B.V., J.M.G.).
Aditya A JoshiCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (N.N.M., A.A.J., A.K.D., C.L.H., M.P.P.).
Amit K DeyCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (N.N.M., A.A.J., A.K.D., C.L.H., M.P.P.).
April W ArmstrongUniversity of Pennsylvania, Philadelphia. Department of Dermatology, University of Southern California, Los Angeles (A.W.A.).
Kristina Callis DuffinDepartment of Dermatology, University of Utah, Salt Lake City (K.C.D.).
Zelma Chiesa FuxenchDepartment of Dermatology, Perelman School of Medicine (D.B.S., Z.C.F., J.T., S.B.V., J.M.G.).
Charlotte L HarringtonCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (N.N.M., A.A.J., A.K.D., C.L.H., M.P.P.).
Rebecca A HubbardDepartment of Epidemiology and Biostatistics, Perelman School of Medicine (R.A.H., J.T., A.B.T., J.M.G.).
Robert E KalbDepartment of Dermatology, Buffalo School of Medicine and Biomedical Sciences, State University of New York (R.E.K.).
Alan MenterDepartment of Dermatology, Baylor University Medical Center, Dallas, TX (A.M.).
Daniel J RaderDepartment of Genetics (D.J.R.).
Muredach P ReillyDepartment of Cardiology, Division of Medicine, Vagelos College of Physician and Surgeons, and the Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY (M.P.R.).
Eric L SimpsonDepartment of Dermatology, Oregon Health & Science University, Portland (E.L.S.).
Junko TakeshitaDepartment of Dermatology, Perelman School of Medicine (D.B.S., Z.C.F., J.T., S.B.V., J.M.G.).
Drew A TorigianDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia (D.A.T., T.J.W., A.A.).
Thomas J WernerDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia (D.A.T., T.J.W., A.A.).
Andrea B TroxelDepartment of Epidemiology and Biostatistics, Perelman School of Medicine (R.A.H., J.T., A.B.T., J.M.G.).
Stephen K TyringDepartment of Dermatology, McGovern Medical School at Houston, TX (S.K.T.).
Suzette Baez VanderbeekDepartment of Dermatology, Perelman School of Medicine (D.B.S., Z.C.F., J.T., S.B.V., J.M.G.).
Abby S Van VoorheesDepartment of Dermatology, Eastern Virginia Medical School, Norfolk (A.S.V.V.).
Martin P PlayfordCardiopulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (N.N.M., A.A.J., A.K.D., C.L.H., M.P.P.).
Mark A AhlmanDepartment of Radiology and Imaging Sciences, National Institutes of Health Clinical Research Center, Bethesda, MD (M.A.A.).
Abass AlaviDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia (D.A.T., T.J.W., A.A.).
Joel M GelfandDepartment of Dermatology, Perelman School of Medicine (D.B.S., Z.C.F., J.T., S.B.V., J.M.G.) nehal.mehta@nih.gov Joel.Gelfand@uphs.upenn.edu.
Center for Clinical Research (United States) · USNational Institutes of Health Clinical Center · US

Funding

Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic disease (PACI) InitiativeZIAHL006193 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2014 to 2023
$25.0M
Penn Dermatology Research Training ProgramT32AR007465 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice, David Joel Margolis · 1986 to 2026
$9.0M
In-vitro and Pre-clinical Translational Studies of Inflammation and AtherosclerosisZIAHL006235 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2018 to 2023
$6.7M
A trial to determine the effect of psoriasis treatment on cardiometabolic diseaseR01HL111293 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GELFAND, JOEL M · 2012 to 2017
$3.8M
Psoriasis and the Risk of DiabetesK24AR064310 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI GELFAND, JOEL M · 2013 to 2017
$870k
Intramural NIH HHS ZIA HL006193NHLBI NIH HHS R01 HL111293NIAMS NIH HHS K24 AR064310NIAMS NIH HHS T32 AR007465
6 · The paper itself

Abstract

backgroundPsoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality. We aimed to assess and compare the effect of treatment of moderate-to-severe psoriasis with adalimumab or phototherapy on vascular inflammation and cardiovascular biomarkers. METHODS AND

resultsRandomized, double-blind, trial of adalimumab, phototherapy, and placebo (1:1:1) for 12 weeks, with crossover to adalimumab for 52 weeks total. Outcomes included vascular inflammation by

conclusionsAdalimumab reduced key markers of inflammation including glycoprotein acetylation compared with phototherapy with no effect on glucose metabolism and vascular inflammation, and potential adverse effects on high-density lipoprotein. Glycoprotein acetylation improvement may partially explain the beneficial effects of adalimumab seen in observational studies. Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifiers: NCT01866592 and NCT01553058.

Indexed as

Ultraviolet TherapyAdalimumabAdultAnti-Inflammatory AgentsBiomarkersBlood GlucoseCholesterol, HDLCross-Over StudiesDouble-Blind MethodFemaleFluorodeoxyglucose F18HumansInflammation MediatorsInsulin ResistanceMaleMiddle AgedAdalimumabAnti-Inflammatory AgentsBiomarkersBlood GlucoseCholesterol, HDLFluorodeoxyglucose F18Inflammation MediatorsRadiopharmaceuticalsadalimumabbiomarkersinflammationpsoriasis

Identifiers

PMID29776990
PMCPMC5991103
OpenAlexW2804753859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.